November 19, 2019 — Since Maquet/Datascope first recalled all of its intra-aortic balloon pumps (...
Cardiogenic Shock
This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page.
November 19, 2019 — Since Maquet/Datascope first recalled all of its ...
November 4, 2019 — Abbott is recalling its CentriMag Acute Circulatory Support System due to a calibration system...
Henry Ford Hospital thought leaders...
There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the...
A discussion with William...
May 20, 2019 – A newly released expert consensus statement proposes a classification schema for...
May 14, 2019 — The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and...
This podcast is a discussion with ...

Two device technologies raised concerns in the industry based on recently released clinical data. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.
Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based...
The U.S. Food and Drug Administration (FDA) sent a letter to cardiologists this week to explain its evaluation of...
Nevin Kapur, M.D.,...